Cancer drug break tested: can patients safely pause treatment?

NCT ID NCT01303094

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

Summary

This study tested whether patients with advanced soft tissue sarcoma whose cancer was controlled after six cycles of chemotherapy should continue treatment or take a planned break. Fifty-three patients whose cancer had not progressed were randomly assigned to either keep receiving the drug Trabectedin or to stop it and restart only if their cancer worsened. The goal was to compare side effects and how long the cancer stayed controlled under each approach.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CHU Timone Adultes

Marseille, 13385, France
Centre Antoine Lacassagne

Nice, 06189, France
Centre François Baclesse

Caen, 14076, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Léon Bérard

Lyon, 69008, France
Centre Oscar Lambret

Lille, 59020, France
Centre René Huguenin

Saint-Cloud, 92210, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut Curie

Paris, 75005, France
Institut Gustave Roussy

Villejuif, 94805, France
Léon Bérard Center

Lyon, 69 008, France
Paoli Calmette Institute

Marseille, 13 273, France
Saint-Jacques Hospital

Besançon, 25 000, France

Conditions

Explore the condition pages connected to this study.

SOFT TISSUE SARCOMA UTERINE SARCOMA